ImmunityBio (IBRX) Competitors $2.37 -0.09 (-3.66%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.38 +0.01 (+0.42%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBRX vs. VRNA, BBIO, BPMC, LEGN, RGC, ROIV, ELAN, RVMD, GRFS, and TGTXShould you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Regencell Bioscience (RGC), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. ImmunityBio vs. Its Competitors Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Legend Biotech Regencell Bioscience Roivant Sciences Elanco Animal Health Revolution Medicines Grifols TG Therapeutics Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Which has better valuation & earnings, VRNA or IBRX? Verona Pharma PLC American Depositary Share has higher revenue and earnings than ImmunityBio. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerona Pharma PLC American Depositary Share$42.28M211.78-$173.42M-$2.00-52.59ImmunityBio$14.74M141.91-$413.56M-$0.58-4.09 Do analysts rate VRNA or IBRX? Verona Pharma PLC American Depositary Share presently has a consensus price target of $109.00, suggesting a potential upside of 3.63%. ImmunityBio has a consensus price target of $12.25, suggesting a potential upside of 416.88%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verona Pharma PLC American Depositary Share 0 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.15ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media favor VRNA or IBRX? In the previous week, Verona Pharma PLC American Depositary Share had 6 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for Verona Pharma PLC American Depositary Share and 5 mentions for ImmunityBio. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.22 beat ImmunityBio's score of 0.64 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verona Pharma PLC American Depositary Share 8 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in VRNA or IBRX? 85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 4.8% of Verona Pharma PLC American Depositary Share shares are held by insiders. Comparatively, 76.8% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is VRNA or IBRX more profitable? Verona Pharma PLC American Depositary Share has a net margin of 0.00% compared to ImmunityBio's net margin of -1,310.30%. ImmunityBio's return on equity of 0.00% beat Verona Pharma PLC American Depositary Share's return on equity.Company Net Margins Return on Equity Return on Assets Verona Pharma PLC American Depositary ShareN/A -69.65% -28.00% ImmunityBio -1,310.30%N/A -121.88% Which has more volatility & risk, VRNA or IBRX? Verona Pharma PLC American Depositary Share has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. SummaryVerona Pharma PLC American Depositary Share and ImmunityBio tied by winning 8 of the 16 factors compared between the two stocks. Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBRX vs. The Competition Export to ExcelMetricImmunityBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.17B$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-4.0917.6228.6723.80Price / Sales141.91179.18373.9066.58Price / CashN/A41.9535.4557.96Price / Book-4.168.508.275.55Net Income-$413.56M-$55.06M$3.24B$259.03M7 Day Performance-17.13%-3.98%-3.69%-4.59%1 Month Performance-10.23%9.59%4.33%4.46%1 Year Performance-49.36%6.72%25.95%18.03% ImmunityBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBRXImmunityBio2.2348 of 5 stars$2.37-3.7%$12.25+416.9%-50.5%$2.17B$14.74M-4.09590News CoverageGap DownVRNAVerona Pharma PLC American Depositary Share2.1954 of 5 stars$104.980.0%$109.00+3.8%+365.2%$8.94B$42.28M-52.4930Positive NewsUpcoming EarningsShort Interest ↑BBIOBridgeBio Pharma4.7123 of 5 stars$45.94+0.4%$61.50+33.9%+80.9%$8.68B$127.42M-12.95400Upcoming EarningsAnalyst ForecastBPMCBlueprint Medicines1.0661 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Upcoming EarningsLEGNLegend Biotech3.5917 of 5 stars$44.86+1.9%$73.33+63.5%-29.5%$8.25B$728.30M-76.072,609Positive NewsRGCRegencell Bioscience0.0502 of 5 stars$16.36+19.7%N/AN/A$8.09BN/A0.0010ROIVRoivant Sciences1.8472 of 5 stars$11.51+0.1%$16.50+43.3%+6.5%$7.81B$29.05M-45.98860Positive NewsUpcoming EarningsELANElanco Animal Health3.8056 of 5 stars$15.11+1.2%$16.00+5.9%+5.9%$7.50B$4.44B20.419,000Positive NewsUpcoming EarningsRVMDRevolution Medicines4.467 of 5 stars$38.66+1.0%$68.91+78.2%-19.1%$7.18B$11.58M-9.63250News CoveragePositive NewsUpcoming EarningsGRFSGrifols3.1017 of 5 stars$9.89+2.4%$10.30+4.1%+41.1%$6.78B$7.81B8.4223,822Dividend AnnouncementTGTXTG Therapeutics4.0843 of 5 stars$38.45+2.9%$43.80+13.9%+85.0%$6.09B$329M159.92290Positive NewsUpcoming Earnings Related Companies and Tools Related Companies VRNA Alternatives BBIO Alternatives BPMC Alternatives LEGN Alternatives RGC Alternatives ROIV Alternatives ELAN Alternatives RVMD Alternatives GRFS Alternatives TGTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IBRX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IBRX Stock Alerts